Shopping Cart
Remove All
Your shopping cart is currently empty
WB518 is a potent STAT3 inhibitor. It effectively suppresses STAT3 activity and the expression of keratin 17. By inhibiting STAT3 phosphorylation and keratin 17, WB518 can significantly alleviate imiquimod and TPA-induced psoriasis in animal models.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | WB518 is a potent STAT3 inhibitor. It effectively suppresses STAT3 activity and the expression of keratin 17. By inhibiting STAT3 phosphorylation and keratin 17, WB518 can significantly alleviate imiquimod and TPA-induced psoriasis in animal models. |
| In vitro | WB518 (5-25 μM) significantly reduces the mRNA and protein levels of keratin 17 (K17) in HaCaT cells by inhibiting the phosphorylation of STAT3 Tyr705 (Y705). |
| In vivo | Topical application of WB518 (at doses of 17.5 μg and 35 μg per site, daily for 5 days) alleviates TPA-induced psoriasis-like skin inflammation and significantly improves the phenotypic characteristics in a mouse model of psoriasis. |
| Formula | C20H16BrN5O5S |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.